Report cover image

Hypoparathyroidism Treatment Market - By Product Type (Supplements [Calcium, Vitamin D, Magnesium, Zinc], Parathyroid Hormone), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) & Forecast, 2024 - 2032

Publisher Global Market Insights
Published Feb 28, 2024
Length 165 Pages
SKU # GMI18756059

Description

Hypoparathyroidism Treatment Market - By Product Type (Supplements [Calcium, Vitamin D, Magnesium, Zinc], Parathyroid Hormone), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacy, Retail Pharmacy) & Forecast, 2024 - 2032


Hypoparathyroidism Treatment Market size is expected to grow at 6.9% CAGR during 2024-2032, driven by growing awareness about treatment options, technological advancements in healthcare, and rising geriatric population. The increasing prevalence of hypoparathyroidism is a primary driver propelling the market growth. Hypoparathyroidism, characterized by abnormally low levels of parathyroid hormone (PTH), affects a substantial portion of the global population.

As per Medscape.com in 2022, primary hyperparathyroidism exhibited a higher prevalence among women, with an incidence of 66 per 100,000 person-years, compared to 25 per 100,000 person-years in males. Factors, such as genetic predisposition, autoimmune disorders, surgical interventions involving the thyroid or parathyroid glands, and other underlying medical conditions are contributing to the rising incidence of hypoparathyroidism. As awareness about this endocrine disorder grows among healthcare professionals and the general population, there is a corresponding increase in the diagnosis and treatment of the condition. This surge in diagnosed cases necessitates a corresponding rise in the demand for effective treatment options. Consequently, pharmaceutical companies and healthcare providers are investing in R&D efforts to introduce innovative therapies and improve existing treatment modalities, adding to the market growth.

The hypoparathyroidism treatment industry is segmented into product type, route of administration, distribution channel and region.

The market share from the parathyroid hormone (PTH) product type segment is anticipated to register 7.2% growth rate till 2032. PTH replacement therapy, such as synthetic PTH analogs, is considered the gold standard treatment for hypoparathyroidism. These therapies work by replenishing the deficient levels of PTH in the body, thereby restoring calcium and phosphate balance and further enhancing the segment growth.

By distribution channel, the hypoparathyroidism treatment market from the retail pharmacy segment will record 6.4% CAGR from 2024 to 2032, as they provide convenient access to medications for patients suffering from hypoparathyroidism. Retail pharmacies offer a wide range of hypoparathyroidism treatment options, including prescription medications and over-the-counter supplements, making them a preferred choice for patients seeking regular refills and consultations. The convenience and accessibility offered by retail pharmacies will also contribute to their growing prominence in the distribution of hypoparathyroidism treatments.

Asia Pacific hypoparathyroidism treatment industry is set to gain prominence at 7.4% CAGR till 2032, driven by increasing healthcare expenditure, growing prevalence of hypoparathyroidism, and rising awareness about the condition and its management. Government initiatives aimed at improving healthcare infrastructure and expanding access to essential medications are further fueling the market growth in countries like China, India, and Japan.

Table of Contents

165 Pages
Chapter 1 Methodology & Scope
1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 360 degree synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing parathyroid disorders
3.2.1.2 Increasing government initiatives
3.2.1.3 Rising technological advancements
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Associated side effects
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Porter's analysis
3.5.1 Supplier power
3.5.2 Buyer power
3.5.3 Threat of new entrants
3.5.4 Threat of substitutes
3.5.5 Industry rivalry
3.6 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive positioning matrix
4.4 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Product Type, 2018 - 2032 ($ Mn)
5.1 Key trends
5.2 Supplements
5.2.1 Calcium supplements
5.2.2 Vitamin D supplements
5.2.3 Other supplements
5.2.3.1 Magnesium
5.2.3.2 Zinc
5.3 Parathyroid hormone
Chapter 6 Market Estimates and Forecast,By Route of Administration 2018 - 2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)
7.1 Key trends
7.2 Hospital pharmacy
7.3 Retail pharmacy
7.4 Online pharmacy
Chapter 8 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 South Africa
8.6.3 Rest of Middle East & Africa
Chapter 9 Company Profiles
9.1 Ascendis Pharma A/S
9.2 Amgen Inc.
9.3 BioNTech SE
9.4 Bristol-Myers Squibb Company
9.5 Entera Bio Ltd.
9.6 F. Hoffmann-La Roche Ltd.
9.7 Merck & Co., Inc.
9.8 SK biopharmaceuticals Co., Ltd.
9.9 Sun Pharmaceutical Industries Ltd.
9.10 Takeda Pharmaceutical Company Limited.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us